Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies

被引:131
作者
Hazlehurst, LA
Dalton, WS
机构
[1] Univ S Florida, Dept Pharmacol & Therapeut, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[3] Univ S Florida, Dept Biochem, Tampa, FL 33612 USA
[4] Univ S Florida, Dept Pharmacol, Tampa, FL 33612 USA
[5] Univ S Florida, Clin Invest Program, Tampa, FL 33612 USA
关键词
CAM-DR; beta1; integrins; p27kip1; topoisomerase II; drug resistance;
D O I
10.1023/A:1013156407224
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor microenvironment is often overlooked when considering tumor response to chemotherapeutic agents. This environment consists of soluble factors, components of the extracellular matrix as well as cell-cell interactions. Recently, it has become clear that cell-cell and cell-matrix interactions result in cytoskeletal reorganization and the activation of multiple signal transduction pathways that directly influence cell survival, growth and differentiation. Experimental evidence shows that anti-apoptotic pathways initiated by cell adhesion are operative in tumor cells and, furthermore, cause resistance to mechanistically distinct cytotoxics. For hematopoietic tumors, cell adhesion to a single matrix, fibronectin is sufficient to inhibit apoptosis induced by mechanistically distinct cyctotoxics. Adhesion of hematopoietic tumors to this matrix blocks cell cycle progression, and for the human multiple myeloma 8226 cell line adhesion to fibronectin resulted in increased p27kip1 levels, which correlated with cell cycle arrest and drug resistance. A decrease in initial DNA damage induced by topoisomerase 11 inhibitors has also been observed in adherent hematopoietic tumor cell lines. Further studies investigating the mechanisms of cell adhesion mediated drug resistance may reveal novel targets directed at the reversal of de novo drug resistance.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 54 条
[41]   INHIBITION OF CELL-CYCLE PROGRESSION BY THE ALTERNATIVELY SPLICED INTEGRIN BETA(1C) [J].
MEREDITH, J ;
TAKADA, Y ;
FORNARO, M ;
LANGUINO, LR ;
SCHWARTZ, MA .
SCIENCE, 1995, 269 (5230) :1570-1572
[42]   DRUG AND RADIATION-RESISTANCE IN SPHEROIDS - CELL CONTACT AND KINETICS [J].
OLIVE, PL ;
DURAND, RE .
CANCER AND METASTASIS REVIEWS, 1994, 13 (02) :121-138
[43]  
Oloumi A, 2000, CANCER RES, V60, P5747
[44]   P27(KIP1), A CYCLIN-CDK INHIBITOR, LINKS TRANSFORMING GROWTH-FACTOR-BETA AND CONTACT INHIBITION TO CELL-CYCLE ARREST [J].
POLYAK, K ;
KATO, JY ;
SOLOMON, MJ ;
SHERR, CJ ;
MASSAGUE, J ;
ROBERTS, JM ;
KOFF, A .
GENES & DEVELOPMENT, 1994, 8 (01) :9-22
[45]   Fetal and adult hematopoietic stem cells require β1 integrin function for colonizing fetal liver, spleen, and bone marrow [J].
Potocnik, AJ ;
Brakebusch, C ;
Fässler, R .
IMMUNITY, 2000, 12 (06) :653-663
[46]   Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds β1 integrins, collagens and fibronectin [J].
Sasaki, T ;
Brakebusch, C ;
Engel, J ;
Timpl, R .
EMBO JOURNAL, 1998, 17 (06) :1606-1613
[47]   Extracellular matrix proteins protect small cell lung cancer cells against apoptosis:: A mechanism for small cell lung cancer growth and drug resistance in vivo [J].
Sethi, T ;
Rintoul, RC ;
Moore, SM ;
MacKinnon, AC ;
Salter, D ;
Choo, C ;
Chilvers, ER ;
Dransfield, I ;
Donnelly, SC ;
Strieter, R ;
Haslett, C .
NATURE MEDICINE, 1999, 5 (06) :662-668
[48]   Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors [J].
St Croix, B ;
Man, S ;
Kerbel, RS .
CANCER LETTERS, 1998, 131 (01) :35-44
[49]   E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1 [J].
St Croix, B ;
Sheehan, C ;
Rak, JW ;
Florenes, VA ;
Slingerland, JM ;
Kerbel, RS .
JOURNAL OF CELL BIOLOGY, 1998, 142 (02) :557-571
[50]  
StCroix B, 1996, NAT MED, V2, P1204